Αποτελέσματα Αναζήτησης
ONCEPT ® Canine Melanoma Vaccine, DNA aids in extending survival times of dogs with stage II or stage III oral melanoma and for which local disease control has been achieved (negative local lymph nodes or positive lymph nodes that were surgically removed or irradiated). 1
The Oncept melanoma vaccine is xenogeneic DNA vaccine targeting tyrosinase. It is USDA approved for treatment of stage II to III canine oral melanoma and is also used off-label for melanomas arising in other locations and in other species.
12 Φεβ 2019 · This review will cover the most relevant immunotherapeutic strategies for the treatment of canine malignant melanoma, divided among five different categories, namely, monoclonal antibodies, nonspecific immunotherapy activated by bacteria, vaccines, gene therapy, and lymphokine-activated killer cell therapy.
1 Απρ 2003 · In this study, we demonstrate that human tyrosinase DNA vaccination of dogs with advanced malignant melanoma is safe and potentially active, warranting additional xenogeneic DNA vaccine investigations as Phase II studies in CMM and Phase I studies for HM.
Systemic immunotherapy for adjuvant treatment of canine melanoma may be more promising than chemotherapy. A xenogeneic DNA vaccine, Oncept (Boehringer Ingelheim, petcancervaccine.com ), has made headway as the first conditionally approved immunotherapy for the treatment of canine OMM.
10 Ιουλ 2016 · This study showed that the canine melanoma DNA vaccine (Oncept) can safely be administered to cats, with minimal risk of adverse effects.
The University of Florida College of Veterinary Medicine is currently recruiting dogs recently diagnosed with malignant melanoma for a clinical research trial. This investigational trial is for the development of a vaccine for the future treatment or prevention of melanoma in dogs.
